Moreover, although several studies have shown that brevilin A treatment results in activation of JNK and p38 (Wang et al., 2018), and inactivation of Akt in cancer cells (Qu et al., 2020), our results showed that brevilin A did not affect LPS/IFNγ-induced activation of MAPKs and Akt in RAW264.7 cells. The gene discussed is AKT1; the disease is cancer.